{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360016870094094848.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.ejmech.2021.113730"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0223523421005791?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0223523421005791?httpAccept=text/plain"}}],"dc:title":[{"@value":"Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380016870094094850","@type":"Researcher","foaf:name":[{"@value":"Xin Qiao"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094855","@type":"Researcher","foaf:name":[{"@value":"Yu-Yang Gao"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094852","@type":"Researcher","foaf:name":[{"@value":"Li-Xia Zheng"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094853","@type":"Researcher","foaf:name":[{"@value":"Xiao-Jing Ding"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094848","@type":"Researcher","foaf:name":[{"@value":"Ling-Wen Xu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094854","@type":"Researcher","foaf:name":[{"@value":"Juan-Juan Hu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094851","@type":"Researcher","foaf:name":[{"@value":"Wei-Zhen Gao"}]},{"@id":"https://cir.nii.ac.jp/crid/1380016870094094849","@type":"Researcher","foaf:name":[{"@value":"Jing-Yuan Xu"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02235234"}],"prism:publicationName":[{"@value":"European Journal of Medicinal Chemistry"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2021-11","prism:volume":"223","prism:startingPage":"113730"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license","https://doi.org/10.15223/policy-017","https://doi.org/10.15223/policy-037","https://doi.org/10.15223/policy-012","https://doi.org/10.15223/policy-029","https://doi.org/10.15223/policy-004"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0223523421005791?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0223523421005791?httpAccept=text/plain"}],"createdAt":"2021-07-28","modifiedAt":"2025-10-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/2050870367085358720","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dual-action Pt(Ⅳ) prodrugs and targeted delivery in metal-organic frameworks : overcoming cisplatin resistance and improving anticancer activity"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.ejmech.2021.113730"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20220218_references_DOI_W8GTHztvSdF2RGRtkOAkR5qI5BN"}]}